Mineralocorticoid Receptor Antagonist Use Among Patients With Chronic Kidney Disease Who Transitioned to Dialysis

被引：0
|
作者：
Tong, Eric M. [1 ]
Zhou, Hui [2 ,3 ,4 ]
Pak, Katherine [2 ]
Huang, Cheng-Wei [3 ,4 ,5 ]
Broder, Benjamin I. [2 ,3 ,4 ,6 ]
Sim, John J. [2 ,3 ,4 ,7 ]
机构：
[1] Kaiser Permanente Woodland Hills Med Ctr, Div Nephrol, Woodland Hills, CA USA
[2] Kaiser Permanente Southern Calif, Dept Res & Evaluat, Pasadena, CA USA
[3] Kaiser Permanente Bernard J Tyson Sch Med, Dept Hlth Syst Sci, Pasadena, CA USA
[4] Kaiser Permanente Bernard J Tyson Sch Med, Dept Clin Sci, Pasadena, CA USA
[5] Kaiser Permanente Los Angeles Med Ctr, Dept Hosp Med, Los Angeles, CA 90027 USA
[6] Southern Calif Permanente Med Grp, Reg Qual & Clin Anal, Pasadena, CA USA
[7] Kaiser Permanente Los Angeles Med Ctr, Div Nephrol & Hypertens, 4700 Sunset Blvd, Los Angeles, CA 90027 USA
来源：
KIDNEY MEDICINE | 2025年 / 7卷 / 04期
关键词：
D O I：
10.1016/j.xkme.2025.100973
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Evidence for the use of a nonsteroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease
    Plicas, Mariana Morais David
    da Silva, Bernardo Marques
    de Almeida, Edgar Avito Fernandes
    NEFROLOGIA, 2025, 45 (03): : 214 - 227
  • [2] Mineralocorticoid receptor antagonist for chronic kidney disease, risk or benefit?
    Huang, Bi
    Mcdowell, Garry
    Rao, Anirudh
    Lip, Gregory Y. H.
    JOURNAL OF HYPERTENSION, 2024, 42 (03) : 396 - 398
  • [3] Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease
    Oka, Tatsufumi
    Sakaguchi, Yusuke
    Hattori, Koki
    Asahina, Yuta
    Kajimoto, Sachio
    Doi, Yohei
    Kaimori, Jun-Ya
    Isaka, Yoshitaka
    HYPERTENSION, 2022, 79 (03) : 679 - 689
  • [4] Mineralocorticoid Receptor Antagonist Use in Patients With Heart Failure and Co-Morbid Diabetes or Chronic Kidney Disease
    Cooper, Lauren B.
    Lippmann, Steven J.
    Greiner, Melissa A.
    Kelly, Jacob P.
    Sharma, Abhinav
    Fonarow, Gregg C.
    Yancy, Clyde W.
    Heidenreich, Paul A.
    Hernandez, Adrian F.
    CIRCULATION, 2016, 134
  • [5] Mineralocorticoid Receptor Antagonist Use in Patients With Heart Failure and Co-Morbid Diabetes or Chronic Kidney Disease
    Cooper, Lauren B.
    Lippmann, Steven J.
    Greiner, Melissa A.
    Kelly, Jacob P.
    Sharma, Abhinav
    Fonarow, Gregg C.
    Yancy, Clyde W.
    Heidenreich, Paul A.
    Hernandez, Adrian F.
    CIRCULATION, 2016, 134
  • [6] Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease
    Raj, Rajesh
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2022, 31 (03): : 265 - 271
  • [7] Mineralocorticoid receptor antagonists in patients with chronic kidney disease
    Cosimato, Cosimo
    Agoritsas, Thomas
    Mavrakanas, Thomas A.
    PHARMACOLOGY & THERAPEUTICS, 2021, 219
  • [8] Mineralocorticoid Receptor Antagonists-Use in Chronic Kidney Disease
    Baran, Wiktoria
    Krzeminska, Julia
    Szlagor, Magdalena
    Wronka, Magdalena
    Mlynarska, Ewelina
    Franczyk, Beata
    Rysz, Jacek
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (18)
  • [9] The mineralocorticoid receptor in chronic kidney disease
    Barrera-Chimal, Jonatan
    Jaisser, Frederic
    Anders, Hans-Joachim
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (13) : 3152 - 3164
  • [10] Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
    DeFronzo, Ralph A.
    Bakris, George L.
    DIABETES OBESITY & METABOLISM, 2022, 24 (07): : 1197 - 1205
12345